European Respiratory Society Monograph, Vol. 75. 2017
ISBN (electronic): 978-1-84984-084-2
DOI: 10.1183/2312508X.erm7517
Pulmonary infections are a major cause of morbidity and mortality worldwide. Adequate and timely treatment of these infections is therefore of vital importance, especially when considering the emerging problem of antimicrobial resistance. This Monograph provides a comprehensive up-to-date overview of the use of anti-infectives in lung diseases, with chapters covering community- and hospital-acquired pneumonia, exacerbations of asthma and chronic obstructive pulmonary disease, tuberculosis and nontuberculous mycobacteria pulmonary disease, pleural infections, and fungal diseases. Other chapters address antibiotic stewardship in the community and hospital settings, and the use of antibiotics in specific patient groups (e.g. critically ill and paediatric patients). Mechanisms of action and resistance, diagnostic approaches, therapeutic options (e.g. combination therapy, dosing and routes of administration), and the development of new drugs are also discussed.
Preface Robert Bals Eur Respir Monogr 2017; 75: v-vi |  |
Guest Editors
Eur Respir Monogr 2017; 75: vii-ix |  |
Introduction Stefano Aliberti, James D. Chalmers, Mathias W. Pletz Eur Respir Monogr 2017; 75: x-xii |  |
List of abbreviations
Eur Respir Monogr 2017; 75: xii |  |
Antibiotics for pulmonary infections: an overview Matteo Bassetti, Elda Righi Eur Respir Monogr 2017; 75: 1-20 |   |
Antibiotic resistance in pulmonary infections: mechanisms and epidemiology Oliwia Makarewicz, Mareike Klinger-Strobel, Ralf Ehricht, Michael Kresken, Mathias W. Pletz Eur Respir Monogr 2017; 75: 21-43 |   |
Antibiotics in critical care: dosing, therapeutic drug monitoring and continuous infusions Maya Hites, Fabio Silvio Taccone Eur Respir Monogr 2017; 75: 44-56 |   |
Inhaled antibiotics in chronic airway infections Felix C. Ringshausen, James D. Chalmers, Mathias W. Pletz Eur Respir Monogr 2017; 75: 57-79 |   |
Inhaled antibiotics in critical care Charles-Edouard Luyt, Jean Chastre Eur Respir Monogr 2017; 75: 80-96 |   |
Identifying patients with pneumonia due to MDR organisms coming from the community Marta Di Pasquale, Stefano Aliberti, Paolo Tarsia, Francesco Blasi Eur Respir Monogr 2017; 75: 97-110 |   |
Antibiotic stewardship in the community Eleni Papakonstantinou, Daiana Stolz Eur Respir Monogr 2017; 75: 111-126 |   |
Antibiotic stewardship in the hospital setting James D. Chalmers, Mathias W. Pletz Eur Respir Monogr 2017; 75: 127-149 |   |
Antibiotics in acute exacerbation of asthma and COPD Gernot G.U. Rohde Eur Respir Monogr 2017; 75: 150-158 |   |
Antifungals in pulmonary infections: to whom, when and how? Sebastian R. Ott Eur Respir Monogr 2017; 75: 159-184 |   |
Long-term oral antibiotic treatment: why, what, when and to whom? Eva Van Braeckel, Menno M. van der Eerden Eur Respir Monogr 2017; 75: 185-205 |   |
Macrolide therapy for patients with pneumonia: a triple-edged sword Yuichiro Shindo, Yoshinori Hasegawa Eur Respir Monogr 2017; 75: 206-231 |   |
Treatment options for MDR- and XDR-TB Kwok Chiu Chang, Giovanni Sotgiu Eur Respir Monogr 2017; 75: 232-244 |   |
Perspectives on antibiotic treatment of NTM pulmonary disease Nicolas Schönfeld Eur Respir Monogr 2017; 75: 245-252 |   |
Antibiotics for pleural infections Rahul Bhatnagar, Vasileios S. Skouras, Najib M. Rahman, Ioannis Psallidas Eur Respir Monogr 2017; 75: 253-263 |   |
Antibiotics in interstitial lung diseases Davide Biondini, Paolo Spagnolo Eur Respir Monogr 2017; 75: 264-275 |   |
Insights into antibiotic use in children with CAP Susanna Esposito, Mara Lelii, Rossana Tenconi, Maria Francesca Patria Eur Respir Monogr 2017; 75: 276-288 |   |
New antibiotic development for pulmonary infections: New Drugs for Bad Bugs and beyond Tomislav Kostyanev, Marc J.M. Bonten, Herman Goossens Eur Respir Monogr 2017; 75: 289-301 |   |
Combination antibiotic therapy and synergy in HAP and VAP Rodrigo Cavallazzi, Julio A. Ramirez Eur Respir Monogr 2017; 75: 302-311 |   |